Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-022-02641-5
Abstract: The oral factor Xa inhibitors (OFXAi) apixaban and rivaroxaban are increasingly utilized for the treatment of venous thromboembolism (VTE) with recommended initial higher dose 7- and 21-day lead-in regimens, respectively. In patients receiving initial parenteral… read more here.
Keywords: venous thromboembolism; apixaban rivaroxaban; treatment venous; lead group ... See more keywords